Figure 3 | Scientific Reports

Figure 3

From: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

Figure 3The alternative text for this image may have been generated using AI.

Summary of Neutralizing Antibodies (nAb) against Omicron B.1.1.529 at each visit (Per protocol population). GMT: Geometric Mean Titer. For each study vaccine, the GMT of Neutralizing Antibodies (nAb) and 95% CI were calculated by transforming to the original scale of log10-transformed mean and its two-sided 95% CI limits at each visit.

Back to article page